drugset
drugset / Trial / NCT01433445

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

NCT01433445 ↗

Phase 1 Completed 61 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will assess safety as well as establish a Recommended Phase II dose of the combination of panobinostat and ruxolitinib in patients with or without the JAK2V617F mutation who have been diagnosed with primary myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (PET MF), or Post-Polycythemia Vera Myelofibrosis (PPV MF).

Timeline

Start
2011-11-01
Primary completion
2020-06-22
Completion
2020-06-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Panobinostat Small molecule 10 mg Oral
Subject Panobinostat Small molecule 15 mg Oral
Subject Panobinostat Small molecule 20 mg Oral
Subject Panobinostat Small molecule 25 mg Oral
Subject Ruxolitinib Small molecule 5 mg Oral
Subject Ruxolitinib Small molecule 10 mg Oral
Subject Ruxolitinib Small molecule 15 mg Oral

Indications

myelofibrosis primary myelofibrosis